Tivorsan Pharmaceuticals, Inc. — Form D
Tivorsan Pharmaceuticals, Inc. of LOS ANGELES, CA, a company, filed a Form D exempt-offering notice with the SEC on 2018-10-25. The offering totals $4.5M, of which $4.5M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2018-10-25
- Form: D
- Accession: 0001615774-18-011318
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $4.5M
- Amount sold: $4.5M
- Minimum investment: $10K
- Investors: 32
- Date of first sale: 2017-03-17
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-324387
Issuer
- Name: Tivorsan Pharmaceuticals, Inc.
- CIK: 0001705703
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 2049 CENTURY PARK EAST, LOS ANGELES, CA, 90067
- Phone: 310-424-1999
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Michael Meyers | Executive Officer | New York, NY |
| Jay Venkatesan | Director | Boston, MA |
| James Connolly | Director | San Francisco, CA |
| John Nicholson | Director | McLean, VA |
| Joel Braunstein | Director | Melbourne, FL |
| Justin Fallon | Director | Los Angeles, CA |
Other filings by this issuer (5)
More